News and Announcements
Strategic Acquisition of ADVANGEN INC., Japan boosts cashflow
- Published May 16, 2013 4:54PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX ANNOUNCEMENT , May 16, 2013
- Immediate access to sales from established Japanese hair growth market
- Whole-of-chain acquisition; reduced cost of goods and no royalties on évolis
- Global rights including China with recently granted import permits
- Boosts Cellmid’s products development expertise to facilitate the midkine hair growth program
Sydney, Wednesday, 8 May 2013: Cellmid Limited (ASX:CDY) is pleased to advise that it will acquire Advangen Inc., Japan (Advangen), the company that owns the FGF-5 inhibitor hair growth technology. This is a high strategic acquisition that will significantly increase Cellmid’s revnues in the short to medium term.
To read the full announcement, please download the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
